Cargando…

The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis

Siponimod is a selective sphingosine 1-phosphate receptor subtype 1 (S1P(1)) and 5 (S1P(5)) modulator approved in the United States and the European Union as an oral treatment for adults with relapsing forms of multiple sclerosis (RMS), including active secondary progressive multiple sclerosis (SPMS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohan, Stanley L., Benedict, Ralph H. B., Cree, Bruce A. C., DeLuca, John, Hua, Le H., Chun, Jerold
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259525/ https://www.ncbi.nlm.nih.gov/pubmed/35725892 http://dx.doi.org/10.1007/s40263-022-00927-z

Ejemplares similares

Siponimod for multiple sclerosis
Publicado: (2021)

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2020)

Prospects of siponimod in secondary progressive multiple sclerosis
por: McGinley, Marisa, et al.
Publicado: (2018)

Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis
por: Regner-Nelke, Liesa, et al.
Publicado: (2022)

Siponimod: A Review in Secondary Progressive Multiple Sclerosis
por: Scott, Lesley J.
Publicado: (2020)

Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study
por: Gold, Ralf, et al.
Publicado: (2022)

Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
por: Gentile, Antonietta, et al.
Publicado: (2016)

Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years
por: Cree, Bruce AC, et al.
Publicado: (2022)

Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
por: Gajofatto, Alberto
Publicado: (2017)

Correction to: Siponimod: A Review in Secondary Progressive Multiple Sclerosis
por: Scott, Lesley J.
Publicado: (2021)

Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial
por: Arnold, Douglas L, et al.
Publicado: (2022)

Efficacy and safety of siponimod for multiple sclerosis: Protocol for a systematic review and meta-analysis
por: Song, Yumeng, et al.
Publicado: (2019)

First in vivo fluorine-19 magnetic resonance imaging of the multiple sclerosis drug siponimod
por: Starke, Ludger, et al.
Publicado: (2023)

Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy
por: Cortesi, Paolo Angelo, et al.
Publicado: (2022)

Pharmacokinetic Characteristics of Siponimod in Healthy Volunteers and Patients With Multiple Sclerosis: Analyses of Published Clinical Trials
por: Chaoyang, Chen, et al.
Publicado: (2022)

Macular edema after siponimod treatment for multiple sclerosis: a case report and literature review
por: Li, Qingsheng, et al.
Publicado: (2023)

COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series
por: Sullivan, Roseanne, et al.
Publicado: (2021)

Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod
por: Krbot Skorić, Magdalena, et al.
Publicado: (2022)

Adequate antibody response to BioNTech COVID vaccine in a multiple sclerosis patient treated with siponimod
por: Siddiqui, Gulnaz, et al.
Publicado: (2021)

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
por: Vališ, Martin, et al.
Publicado: (2023)

Disease reactivation in a patient with secondary progressive multiple sclerosis after switching treatment from fingolimod to siponimod
por: Senzaki, Kensuke, et al.
Publicado: (2021)

Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence
por: Sabsabi, Sajida, et al.
Publicado: (2022)

Disease Reactivation in Secondary Progressive Multiple Sclerosis Patients Switching from Fingolimod to Siponimod: A Case Series
por: Abbadessa, Gianmarco, et al.
Publicado: (2022)

Siponimod ameliorates experimental autoimmune neuritis
por: Uchi, Takafumi, et al.
Publicado: (2023)

Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues
por: Benedict, Ralph H B, et al.
Publicado: (2020)

Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
por: Cohan, Stanley
Publicado: (2016)

Therapeutic effect of combination vitamin D3 and siponimod on remyelination and modulate microglia activation in cuprizone mouse model of multiple sclerosis
por: Al-Otaibi, Kholoud M., et al.
Publicado: (2023)

Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action
por: Behrangi, Newshan, et al.
Publicado: (2019)

Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study
por: Benedict, Ralph HB, et al.
Publicado: (2017)

Acute Lymphoblastic Leukemia in a Man Treated With Fingolimod for Relapsing Multiple Sclerosis
por: Cohan, Stanley, et al.
Publicado: (2015)

Does Siponimod Exert Direct Effects in the Central Nervous System?
por: Kipp, Markus
Publicado: (2020)

Migraine, interferon β1a and siponimod immunomodulator therapies
por: Dahaba, Ashraf A., et al.
Publicado: (2022)

Siponimod Modulates the Reaction of Microglial Cells to Pro-Inflammatory Stimulation
por: Gruchot, Joel, et al.
Publicado: (2022)

Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis
por: Benedict, Ralph HB, et al.
Publicado: (2017)

Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland
por: Schur, Nadine, et al.
Publicado: (2021)

The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Synnott, Patricia G., et al.
Publicado: (2020)

Editorial: Fatigue in Multiple Sclerosis
por: Dettmers, Christian, et al.
Publicado: (2015)

Impact of siponimod on vaccination response in a randomized, placebo-controlled study
por: Ufer, Mike, et al.
Publicado: (2017)

Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models
por: Dietrich, Michael, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oofvidh3rmjq5so6f0r779c4tv